News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.

2020 2019 2018 2017 2016 2015 2014
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
Resverlogix Announces Presentations at Leading Scientific Conferences
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
Resverlogix Announces $13 Million Private Placement
Resverlogix Confirms Interim Filings on SEDAR
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Resverlogix Announces Private Placement
Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
Resverlogix Secures One-Year Extension of Maturity Date of Debenture
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress
Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020
Resverlogix Plans COVID-19 Clinical Trial Program Launch
Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD